A working map of every food, ingredients, agri-tech and food-adjacent cleantech company in Scandinavia, the Benelux, Germany, the Baltics, Poland, France, Iberia, CEE/Balkans/Greece, Austria/Switzerland and the UK/Ireland that closed venture funding between January and April 2026 — ranked by where strategic commercial advisory could move the needle.
These one hundred companies represent the highest-conviction commercial opportunities across all ten regions for Q1 2026 — selected based on stage of scale-up, ingredient or B2B model fit, manufacturing partnership needs, and explicit EMEA expansion mandates. Click through to the regional tabs for the full deal register.
Across all ten regions, precision fermentation, B2B ingredients and sustainable packaging won what little capital there was. Strategic corporate investors — Kubota, Nippon Beet Sugar, DSM-Firmenich, Inter IKEA, Royal Cosun, Oetker, REWE, Lindt & Sprüngli, Corteva, Forbion, Döhler, Paulig, Mondelēz, Lallemand, Bel, Danone, Cargill, Siemens — led disproportionately. The meta-thesis holds: Verley, Standing Ovation, MOA Foodtech, BRAINR, Mewery, Seprify, Planetary, Tropic and Clean Food Group all chose asset-light or partner-led scale over own-build. The UK&I picture is the rest of Europe writ small: AI absorbed the oxygen, alt-protein closed zero rounds, and the smart money rotated upstream into ag-biotech and B2B fermentation. The next 12 months are about commercialization, not capital.
Twenty-three Benelux companies in food, ingredients, agritech, packaging or food-adjacent cleantech raised — or actively scaled with grant capital — in Q1 2026. The strongest near-term prospects cluster in Dutch precision fermentation and functional ingredients, Belgian plant-protein and dairy-replacement plays, and a thin but high-quality bio-based packaging and circular-bioeconomy layer.
Luxembourg yielded only one in-scope deal because Fit 4 Start ran no agri/food vertical this cohort. The wider picture: Dutch agrifood VC volume in Q1 2026 ran roughly two-thirds below its 2024 peak, with grant capital (EU LIFE, EIT Food, CBE-JU, VLAIO) and government co-investors (Invest-NL, BOM, LIOF, PMV, SFPIM) replacing private VC as the dominant fuel. Many of these companies have engineering and capital sorted but lack EMEA commercial channels, co-manufacturing relationships, and brand-distributor introductions.
Twelve German-headquartered startups closed disclosed venture rounds in food, agri-tech, ingredients, biotech-for-food, or sustainable packaging in Q1 2026, totalling roughly €130 million. The pipeline is unusually narrow — German VC capital this year concentrated on AI, defense, and energy, and even the most active food GPs (FoodLabs, Five Seasons, Vorwerk Ventures) announced very few German food deals.
What survived the cut, however, is high-quality and operationally needy. Most of these companies are in scale-up or first-commercial-plant mode — exactly the moment when a fractional advisor with EMEA manufacturing networks adds the most value. Cologne/NRW emerged as the clear cluster (four rounds), followed by Munich/Bavaria, Hamburg, Rostock, and the Lower Saxony "Agrotech Valley." Three companies — Innocent Meat, EVANIUM, and Bioweg — stand out as ideal targets because each one publicly needs co-manufacturing partners and broader European commercial distribution.
The single most defensible commercial wedge in Germany right now is co-manufacturing matchmaking. Innocent Meat needs meat-processor partners. Bioweg needs formulator partners. EVANIUM and Twogee Biotech need ingredient-formulator and supplement-brand partners. MicroHarvest needs feed and pet-food off-takers. BETTER CAKEZ needs LEH and Nordic retail entry.
The strict January–April 2026 window across Estonia, Latvia and Lithuania produced roughly 14 publicly disclosed equity rounds in scope, of which only one is an unambiguous food-supply-chain play (Saltz, €20M Series A in Vilnius). Capital flowed disproportionately to defence/dual-use, AI infrastructure and regtech; pure foodtech, alt-protein and fermentation deals were almost absent.
The standout non-VC event in the window — Pentasweet's €65M brazzein production-plant groundbreaking in Vilnius — is arguably the single most relevant Baltic food-ingredient milestone of Q1 2026 and a likely Series A target later this year. Two Estonian fermentation companies (ÄIO and eAgronom) reached major commercial milestones in the window without closing rounds, making them the highest-probability advisor targets despite the strict criteria. Fresh local capital is queueing up: Baltic Innovation Fund 3 (€225M), FIRSTPICK, Aneli Capital, BSV Ventures, Outlast Fund and Balnord all closed in late 2025/early 2026 — meaning Baltic founders prepping H2 2026 rounds have a notably deeper local cap-table option set than 12 months ago.
The thin Q1 VC quarter masks a thick cohort of post-funding food/ingredient companies in execution mode. With €225M Baltic Innovation Fund 3 and several food-bio-friendly funds (BSV, Voima, Nordic Foodtech VC, SmartCap Green) freshly capitalized, the advisor's window to embed before the next Baltic foodtech raise cycle is approximately the next four to five months.
Only a handful of Polish startups closed venture rounds in food, agri-tech, ingredients, sustainable packaging, or food-relevant biotech between January and April 2026 — far fewer than the broader 2025 baseline would suggest. Q1 2026 Polish VC was overwhelmingly dominated by AI, defence/dual-use, robotics, and healthtech; the country's record-breaking PLN 3.4B 2025 VC year did not translate into a wave of food/ag deals in early 2026.
Realistic in-window targets total roughly 5–7 confirmed deals or industrial events, supplemented by a tightly relevant expanded universe of recently-funded Polish food/ag/packaging companies actively scaling EMEA commercial operations. Polish food-ingredient innovation runs largely on grants (EIC Accelerator, NCBR, PARP, Horizon Europe), not equity — meaning the highest-fit companies have grant runway through 2026 and need exactly what this advisor offers: distribution, brand, and toll-manufacturing relationships. PFR + foodtech.ac "VC Connect: Seed-to-Scale" Edition 2 launches later in 2026 and is the highest-priority program for advisor positioning.
A strict "raised VC in Jan–April 2026" filter under-counts the real Polish opportunity by an order of magnitude. The advisor's value proposition fits best with companies that already have a recent equity or grant round in hand and are now executing on European commercial scale-up. Single in-window match: Proteine Resources' Q1 2026 commercial launch. Single largest in-window industrial event: PsiBufet's PLN 360M Zabrze plant inauguration. Direct engagement with foodtech.ac and PFR's VC Connect Edition 2 program is the highest-leverage move.
Q1 2026 was a quiet but quality-heavy quarter for French food and agritech VC. Roughly 20 in-scope deals closed between January and April 25, 2026, totalling about €230M — well below the 2022–23 peak but concentrated in B2B precision fermentation, biostimulants and bio-ingredient scale-ups, exactly the segments where toll-manufacturing, EMEA market entry and brand-to-manufacturer matchmaking unlock the next stage of growth.
Two precision fermentation rounds — Verley (€32M) and Standing Ovation (€30M) — alone account for ~27% of in-scope capital and both have explicitly chosen asset-light, CMO-led scale-up strategies. The French foodtech ecosystem overall continues to contract (DigitalFoodLab projects ~€290M for full-year 2025, –35% YoY), which sharpens the case for outside commercial firepower: founders are being pushed to monetize earlier and to enter Northern European customer bases sooner. Several deals were led or co-led by Bpifrance France 2030 vehicles, meaning founders are publicly committed to industrial scale-up milestones and likely receptive to outside commercial help to hit them.
Q1 2026 French food and agritech is no longer a CapEx-build moment, it is a commercial-execution moment. Verley and Standing Ovation publicly chose toll partners over factories. Kapsera's whole business is toll-encapsulation. Mycophyto, V.Biotech and Veragrow are in the "first plant + EMEA distribution" sprint. Across the top ten, every founder is dealing with the same problem: converting a recently funded technology platform into commercial revenue across Northern European customer bases that are linguistically, culturally and operationally far from Paris or Lyon. The single most actionable next step is direct outreach to Verley, Standing Ovation and Kapsera.
Q1 2026 Iberian food and agri VC deal flow is genuinely thin. Only three to four in-scope rounds closed between January 1 and April 25, 2026, totaling roughly €10.5M of disclosed capital plus one undisclosed Portuguese growth ticket. All three confirmed Spanish deals are Andalusian or Galician, dominated by greenhouse and precision-ag tech, with one plant-based brand. Portugal recorded zero clearly-disclosed food/ag VC rounds in the window.
This matches a broader contraction: Spanish foodtech investment fell ~31% in 2025 to about €123M, and Portuguese Q1 2026 venture activity totaled only $7.2M across all sectors. For prospecting purposes the actionable list is therefore a hybrid: the short Q1 2026 inventory plus a deeper bench of 2024–2025 funded companies still in active execution mode and explicitly looking for EMEA distribution, toll manufacturing and ingredient-customer partnerships. That bench, not the headline quarter, is where the advisor's profile compounds fastest.
The disciplined read of Q1 2026 Iberia is to treat the headline quarter as a tactical anomaly, not a strategic signal. Three to four confirmed in-window deals are too narrow a base for outreach. The real prospecting universe is the ~30–35 company bench from 2024–2025 that closed funding, validated tech or product-market fit, and is now in the commercial-scale phase where French-language fluency, Sweden-based Northern European networks and toll-manufacturing matchmaking convert directly into pipeline. The five highest-conviction first calls are MOA Foodtech, BRAINR, Heura, Tebrio and PFx Biotech. Each has publicly stated expansion priorities that overlap precisely with the advisor's network geography and sectoral specialization.
Only five food, ag, packaging or food-adjacent VC rounds closed across the 14-country scope between January 1 and April 25, 2026, deploying roughly €28–32M of disclosed capital. Greece (Wikifarmer), Croatia (Fasal Bio) and Hungary (ABZ Innovation) carried the quarter; Romania, Bulgaria, Slovakia, Slovenia, Serbia and the rest of the Western Balkans produced zero in-scope pure-play deals.
The structural read is unambiguous: Czech VC posted its lowest deal count in six years, Romania's disclosed activity fell ~82% YoY through February, and Hiventures' new €42M Hungarian fund explicitly excluded food/ag from priority sectors. This is a buyer's market for fractional advisory. Founders who raised in 2024–2025 are hitting the commercialization wall with extended runways but no fresh capital coming until Q3/Q4 2026 at earliest. The most surprising read: sustainable packaging, not alt-protein, has the cleanest fit-and-funded combination in this region.
Stop hunting for Q1 2026 closes and target the 2024–2025 vintage at the commercialization inflection. The shortlist above represents companies that have product, distribution beachheads and capital, but are constrained on EMEA channel depth and co-manufacturing dealcraft. The advisor's profile is a near-perfect overlay on that constraint. Lead with packaging when sequencing outreach: Fasal Bio just closed, MIWA is scaling retail, Cupffee is breaking into QSR, LAM'ON needs converter partners. The five highest-conviction first calls are Juicy Marbles, Mewery, Fasal Bio, Wikifarmer and Verdino.
Thirteen in-scope deals closed across Austria and Switzerland between January 1 and April 25, 2026, deploying approximately €86M of disclosed venture and strategic capital. Switzerland accounted for roughly three quarters of that capital; Austria contributed volume but smaller tickets. Three sub-sectors dominate: functional/B2B ingredients (Neoh, Cosaic, Seprify), biomass and yeast fermentation platforms (Planetary, Cosaic), and bio-based sustainable packaging materials (Noriware, Seprify, Lignovations).
The headline takeaway: a small number of deals, but a remarkably high hit rate, with most rounds sized at exactly the post-seed-to-Series-A inflection where commercial scale-up, toll manufacturing partnerships, and EMEA brand-to-manufacturer matchmaking are critical skill gaps. The corporate-strategic capital is doing the work: Inter IKEA (Seprify), dsm-firmenich Ventures (Cosaic), REWE and Zintinus (Neoh), Royal Cosun and Oetker (Planetary), Raiffeisen-Holding NÖ-Wien (afreshed). Romandie produced the two single-highest-fit deals despite being the smaller linguistic region.
Three are exceptional fits worth direct outreach this quarter: Seprify, Planetary, and Cosaic. Each just closed, each has explicit toll manufacturing and EMEA brand customer dependencies in public commentary, and each has a strategic on the cap table whose existing relationship the advisor can complement rather than compete with. Two more are strong fits with shorter sales cycles: Noriware (regulatory tailwind, immediate need for European converters) and Neoh (B2B ingredient go-to-market is a stated priority and explicitly under-resourced). The structural lesson: track corporate venture activity, not just financial VC. The deepest food and ingredient capital in this corridor in 2026 is flowing through Inter IKEA, dsm-firmenich, Oetker Ventures, Royal Cosun, REWE, Lindt & Sprüngli, Migros Industries, and Bühler.
Eighteen in-scope rounds closed across the United Kingdom and Republic of Ireland between January 1 and April 25, 2026, deploying roughly $148M (~€135M) in disclosed capital. A single deal — Tropic Biosciences' $105M Series C — accounts for over 70% of the total. Strip Tropic out and the region absorbed only ~$43M across 17 rounds, a startling contraction for what is normally Europe's largest food and ag VC market.
Three forces explain the shape of the quarter. First, AI absorbed the oxygen: HSBC/Dealroom data shows AI took ~£5.8B of the UK's £7.8B Q1 2026 total VC. Second, the alt-protein reset has hardened into a structural correction — UK cultivated meat closed zero rounds, Uncommon Bio formally exited, CellRev entered administration, Julienne Bruno collapsed. Third, the smart money rotated upstream into ag-biotech and gene editing, where Corteva and UKI2S concentrated capital across five rounds. Wales and Northern Ireland produced no qualifying VC equity in window. Brexit context still matters for prospecting: UK food brands navigating EU customs frictions since 2021 increasingly need EU manufacturing and distribution partners — precisely the gap a Sweden-based, French-speaking commercial advisor with Benelux/DACH/French/Iberian networks fills.
UK food and ag VC is in its tightest window in a decade; Ireland's barely exists in 2026 outside Enterprise Ireland micro-rounds; Wales and Northern Ireland produced no qualifying equity. The highest-yield outreach is to roughly six companies: Clean Food Group, The Bland Company, All Things Butter, Positive Carbon, Black Bull Biochar and Gutology — all of which combine a current funded balance sheet, a clear continental-Europe expansion need, and the precise commercial gaps a Swedish-based, French-native, manufacturing-partnership-fluent advisor closes faster than the founders alone. The prospecting list expands meaningfully if you fold in 2024–2025-funded UK&I food and ag companies still in active execution mode, where Hoxton Farms, MiAlgae, ENOUGH, Notpla, Mondra and Nuritas each present at least as strong an advisor fit as anything closed in Q1 2026.
The pattern across all 160 qualifying rounds suggests a clear thesis: fermentation-platform ingredient companies preparing to commercialize. Half the deal count, the majority of the commercial opportunity. These companies share three needs: toll manufacturing and co-production partnerships, B2B ingredient channel access to European food manufacturers, and regulatory navigation for novel food applications.
Invest-NL, BOM, LIOF, Oost NL, InnovationQuarter, PMV, SFPIM, VLAIO, EU LIFE and CBE-JU are now writing the cheques. These investors prioritize industrial scale-up and EMEA commercialization milestones — not US-style growth-at-all-costs. That puts a premium on toll-manufacturing, distributor and brand-partnership skills.
Kubota (Kilter), Nippon Beet Sugar (NoMy), GEA (Solar Foods), DSM-Firmenich (Octarine, Vivici), Paulig (Mycoverse), Lallemand (Revyve), Cosun, Cereal Docks. These companies have one industrial channel already opened. The advisory work orbits around channel build-out across remaining EMEA markets, not early customer discovery.
The fermentation-tasting Code of Practice took effect in Q1 2026 (Netherlands first in EU). Multiple EFSA opinions pending. This means Vivici, The Protein Brewery, NoPalm and Those Vegan Cowboys are all simultaneously hitting the moment where they must convert ingredient platforms into branded customer wins.
Q1 2026 was a thinner-than-average quarter. But the rounds that did close concentrated in exactly the segments where strategic commercial advisory is most valuable: precision fermentation, functional ingredients, plant-based whole cuts, bio-based packaging chemistry, and the circular bioeconomy.
For warm intro flow over the next 12 months, ten short lists of funds dominate Benelux, Nordic, German, Baltic, Polish, French, Iberian, CEE, Austrian/Swiss and UK/Irish deal sourcing in this segment.